NOT (NOT) News
Track canonical SquawkNews coverage tagged to NOT, NOT. This hub brings together deduplicated headlines about nasdaqgs, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Novartis plans global regulatory approval for remibrutinib in RMS
Novartis plans to seek regulatory approval for remibrutinib in RMS globally.
EQUITY | Sep 01, 2026, 05:21 AM UTC
H
Novartis to Present Late-Breaking Data at MSToronto2026
Novartis to Present Late-Breaking Data at MSToronto2026
EQUITY | Sep 01, 2026, 05:20 AM UTC
L
Novartis: delay in disability progression achieved
Novartis said a clinically meaningful delay in disability progression was achieved.
EQUITY | Sep 01, 2026, 05:20 AM UTC
L
Novartis Remibrutinib Significantly Reduces Relapse Rates In Phase III RMS Trials
Novartis Remibrutinib Significantly Reduces Relapse Rates In Phase III RMS Trials
EQUITY | Sep 01, 2026, 05:16 AM UTC
M
Novartis remibrutinib trial data in Phase III RMS
TradingView reports Phase III RMS results for Novartis remibrutinib, an oral BTK inhibitor, citing reduced relapse rates and a favorable safety profile.
EQUITY | Sep 01, 2026, 05:15 AM UTC
L
Novartis pauses autoimmune cell therapy studies after deaths
Novartis has paused its autoimmune cell therapy studies following deaths.
EQUITY | Sep 01, 2026, 04:22 AM UTC